KR102438340B1 - 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태 - Google Patents

인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태 Download PDF

Info

Publication number
KR102438340B1
KR102438340B1 KR1020207015664A KR20207015664A KR102438340B1 KR 102438340 B1 KR102438340 B1 KR 102438340B1 KR 1020207015664 A KR1020207015664 A KR 1020207015664A KR 20207015664 A KR20207015664 A KR 20207015664A KR 102438340 B1 KR102438340 B1 KR 102438340B1
Authority
KR
South Korea
Prior art keywords
degrees
cancer
compound
pharmaceutical composition
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207015664A
Other languages
English (en)
Korean (ko)
Other versions
KR20200066380A (ko
Inventor
케빈 웨인 쿤츠
관춘 황
형욱 최
크리스틴 샌더스
스티븐 마티유
아라니 찬다
프랭크 팡
Original Assignee
에피자임, 인코포레이티드
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에피자임, 인코포레이티드, 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에피자임, 인코포레이티드
Priority to KR1020227029511A priority Critical patent/KR102744039B1/ko
Publication of KR20200066380A publication Critical patent/KR20200066380A/ko
Application granted granted Critical
Publication of KR102438340B1 publication Critical patent/KR102438340B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020207015664A 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태 Active KR102438340B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227029511A KR102744039B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261624215P 2012-04-13 2012-04-13
US61/624,215 2012-04-13
PCT/US2013/036193 WO2013155317A1 (en) 2012-04-13 2013-04-11 Salt form of a human hi stone methyltransf erase ezh2 inhibitor
KR1020147030684A KR102120883B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147030684A Division KR102120883B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227029511A Division KR102744039B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태

Publications (2)

Publication Number Publication Date
KR20200066380A KR20200066380A (ko) 2020-06-09
KR102438340B1 true KR102438340B1 (ko) 2022-08-30

Family

ID=49328166

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020147030684A Active KR102120883B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
KR1020207015664A Active KR102438340B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
KR1020247041285A Pending KR20250005505A (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
KR1020227029511A Active KR102744039B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020147030684A Active KR102120883B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247041285A Pending KR20250005505A (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
KR1020227029511A Active KR102744039B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태

Country Status (26)

Country Link
US (7) US9394283B2 (enExample)
EP (4) EP3628670B1 (enExample)
JP (3) JP6255382B2 (enExample)
KR (4) KR102120883B1 (enExample)
CN (2) CN104603130B (enExample)
AU (2) AU2013245878B2 (enExample)
BR (1) BR112014025508B1 (enExample)
CA (1) CA2870005C (enExample)
CY (2) CY1119383T1 (enExample)
DK (3) DK3184523T3 (enExample)
ES (3) ES2617379T3 (enExample)
HR (2) HRP20170295T1 (enExample)
HU (3) HUE060881T2 (enExample)
IL (4) IL282732B2 (enExample)
IN (1) IN2014DN09068A (enExample)
LT (2) LT3184523T (enExample)
MX (2) MX384641B (enExample)
NZ (1) NZ700761A (enExample)
PL (3) PL3184523T3 (enExample)
PT (3) PT2836491T (enExample)
RS (2) RS55690B1 (enExample)
RU (1) RU2658911C2 (enExample)
SG (3) SG10201608577RA (enExample)
SI (2) SI3184523T1 (enExample)
SM (2) SMT201700132T1 (enExample)
WO (1) WO2013155317A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
SG10201608577RA (en) * 2012-04-13 2016-12-29 Epizyme Inc Salt form of a human hi stone methyltransf erase ezh2 inhibitor
EP2836216B1 (en) 2012-04-13 2022-06-08 Epizyme, Inc. Combination therapy for treating cancer
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
NZ706738A (en) 2012-10-15 2018-10-26 Epizyme Inc Substituted benzene compounds
AU2013331368A1 (en) 2012-10-15 2015-04-30 Epizyme, Inc. Methods of treating cancer
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN105308038B (zh) 2013-04-30 2018-05-29 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2的抑制剂
JP2016523955A (ja) 2013-07-10 2016-08-12 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ Ｚｅｓｔｅホモログ２エンハンサー阻害剤
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
LT3057962T (lt) 2013-10-16 2023-12-11 Epizyme, Inc. Hidrochlorido druskos forma, skirta ezh2 inhibavimui
WO2015058125A1 (en) * 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
ES2863996T3 (es) 2013-12-06 2021-10-13 Epizyme Inc Terapia de combinación para el tratamiento del cáncer
JP6779793B2 (ja) 2014-06-17 2020-11-04 エピザイム，インコーポレイティド リンパ腫を治療するためのｅｚｈ２阻害剤
LT3157928T (lt) 2014-06-20 2019-05-27 Constellation Pharmaceuticals, Inc. 2-((4s)-6-(4-chlorfenil)-1-metil-4h-benzo[c]iizoksazolo[4,5-e]azepin-4-il)acetamido kristalinės formos
KR102397720B1 (ko) 2014-10-16 2022-05-13 에피자임, 인코포레이티드 암을 치료하기 위한 방법
HUE062159T2 (hu) * 2014-11-17 2023-10-28 Epizyme Inc Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
MX391720B (es) 2015-04-20 2025-03-21 Epizyme Inc Terapia combinada para tratar cáncer.
MX387885B (es) 2015-06-10 2025-03-19 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
EP3407978A4 (en) 2016-01-29 2020-01-15 Epizyme Inc POLYTHERAPY FOR THE TREATMENT OF CANCER
EP3464643A4 (en) * 2016-06-01 2020-04-01 Epizyme Inc USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
WO2018075598A1 (en) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
US11214561B2 (en) * 2017-01-25 2022-01-04 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
JP2022545467A (ja) 2019-08-22 2022-10-27 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
IL294108A (en) * 2019-12-20 2022-08-01 Epizyme Inc Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer
WO2022208552A1 (en) * 2021-03-31 2022-10-06 Msn Laboratories Private Limited, R&D Center Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140324A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indoles

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
ATE180468T1 (de) 1993-12-27 1999-06-15 Eisai Co Ltd Anthranilsäure derivate
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
JP2002525352A (ja) 1998-09-30 2002-08-13 ザ、プロクター、エンド、ギャンブル、カンパニー ２−置換ケトアミド
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
BR0116539A (pt) 2000-12-28 2003-09-23 Shionogi & Co Derivados de piridona tendo uma atividade de ligação para o receptor 2 do tipo canabinóide
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US20050101590A1 (en) 2002-02-19 2005-05-12 Kiyoshi Yasui Antipruritics
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
WO2005095386A1 (en) 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
EP1765994B1 (en) 2004-06-01 2009-11-18 The University of North Carolina at Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2006130720A2 (en) 2005-06-02 2006-12-07 University Of North Carolina At Chapel Hill Purification, characterization and reconstitution of a ubiquitin e3 ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
KR101347102B1 (ko) 2005-10-19 2014-01-03 그뤼넨탈 게엠베하 신규한 바닐로이드 수용체 리간드 및 약제를 제조하기 위한이의 용도
EP1951672B1 (en) 2005-10-21 2011-05-25 Merck Sharp & Dohme Corp. Potassium channel inhibitors
CA2622615A1 (en) 2005-10-28 2007-05-10 The University Of North Carolina At Chapel Hill Protein demethylases comprising a jmjc domain
JP2009519966A (ja) 2005-12-14 2009-05-21 ブリストル−マイヤーズ スクイブ カンパニー セリンプロテアーゼ阻害剤として有用な６員ヘテロ環
WO2007087015A1 (en) 2006-01-20 2007-08-02 The University Of North Carolina At Chapel Hill Diagnostic and therapeutic targets for leukemia
WO2008073138A2 (en) 2006-05-15 2008-06-19 Irm Llc Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
US20070287706A1 (en) 2006-05-18 2007-12-13 Dickson John K Jr Certain substituted quinolones, compositions, and uses thereof
WO2008108825A2 (en) 2006-10-10 2008-09-12 Burnham Institute For Medical Research Neuroprotective compositions and methods
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009006577A2 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
US8247401B2 (en) 2007-10-31 2012-08-21 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
CN101945869B (zh) 2007-12-19 2014-06-18 癌症研究技术有限公司 吡啶并[2,3-b]吡嗪-8-取代化合物及其用途
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
EP2323660A2 (en) 2008-08-08 2011-05-25 New York Blood Center Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
EP2411007A4 (en) 2009-03-27 2012-12-05 Uab Research Foundation MODULATION OF IRES-MEDIATED TRANSLATION
WO2011011366A2 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
EP2521558A4 (en) 2009-12-30 2013-07-03 Avon Prod Inc TOPICAL LIGHTING COMPOSITION AND USES THEREOF
WO2012005805A1 (en) * 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
RU2765155C2 (ru) 2010-09-10 2022-01-26 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2646020B1 (en) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP3536314A1 (en) 2012-03-12 2019-09-11 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
EP2836216B1 (en) 2012-04-13 2022-06-08 Epizyme, Inc. Combination therapy for treating cancer
SG10201608577RA (en) 2012-04-13 2016-12-29 Epizyme Inc Salt form of a human hi stone methyltransf erase ezh2 inhibitor
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
AU2013331368A1 (en) 2012-10-15 2015-04-30 Epizyme, Inc. Methods of treating cancer
LT3057962T (lt) 2013-10-16 2023-12-11 Epizyme, Inc. Hidrochlorido druskos forma, skirta ezh2 inhibavimui

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140324A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indoles

Also Published As

Publication number Publication date
IL282732B2 (en) 2023-04-01
IL282732B (en) 2022-12-01
ES2931316T3 (es) 2022-12-28
EP4190777A1 (en) 2023-06-07
HRP20170295T1 (hr) 2017-04-21
KR102744039B1 (ko) 2024-12-17
IL296199B1 (en) 2024-08-01
AU2013245878B2 (en) 2017-10-12
AU2018200168B2 (en) 2019-08-29
LT2836491T (lt) 2017-03-27
JP2015512942A (ja) 2015-04-30
ES2617379T3 (es) 2017-06-16
US20150065503A1 (en) 2015-03-05
IL296199A (en) 2022-11-01
DK2836491T3 (en) 2017-03-06
IL266165B (en) 2021-06-30
KR20200066380A (ko) 2020-06-09
SG10201608577RA (en) 2016-12-29
MX362339B (es) 2019-01-11
EP2836491A4 (en) 2015-09-16
EP3184523B1 (en) 2019-06-19
NZ700761A (en) 2016-09-30
AU2018200168A1 (en) 2018-02-01
CN104603130A (zh) 2015-05-06
US20210137936A1 (en) 2021-05-13
RU2658911C2 (ru) 2018-06-26
US20230140327A1 (en) 2023-05-04
CN108358899B (zh) 2021-07-27
SMT201700132T1 (it) 2017-05-08
US10821113B2 (en) 2020-11-03
HUE060881T2 (hu) 2023-04-28
BR112014025508B1 (pt) 2020-11-17
CA2870005A1 (en) 2013-10-17
EP3628670B1 (en) 2022-10-12
JP6634058B2 (ja) 2020-01-22
MX2014012380A (es) 2015-07-23
WO2013155317A1 (en) 2013-10-17
KR20250005505A (ko) 2025-01-09
IL282732A (en) 2021-06-30
MX384641B (es) 2025-03-14
US20170143729A1 (en) 2017-05-25
RS59392B1 (sr) 2019-11-29
CY1122883T1 (el) 2022-03-24
DK3184523T3 (da) 2019-08-19
RS55690B1 (sr) 2017-07-31
PT3628670T (pt) 2022-12-02
JP2018002742A (ja) 2018-01-11
US9394283B2 (en) 2016-07-19
JP6255382B2 (ja) 2017-12-27
HUE031976T2 (en) 2017-08-28
KR20150002730A (ko) 2015-01-07
US20180243316A1 (en) 2018-08-30
LT3184523T (lt) 2020-02-10
CN108358899A (zh) 2018-08-03
US20250268905A1 (en) 2025-08-28
CN104603130B (zh) 2018-04-27
PL2836491T3 (pl) 2017-08-31
US9872862B2 (en) 2018-01-23
PT2836491T (pt) 2017-02-08
EP3628670A1 (en) 2020-04-01
US20190269692A1 (en) 2019-09-05
PT3184523T (pt) 2019-09-26
AU2013245878A1 (en) 2014-10-30
EP2836491B1 (en) 2016-12-07
IN2014DN09068A (enExample) 2015-05-22
SG10201912109QA (en) 2020-02-27
RU2014145544A (ru) 2016-06-10
IL235045A0 (en) 2014-12-31
SI2836491T1 (sl) 2017-06-30
CY1119383T1 (el) 2018-02-14
HUE045353T2 (hu) 2019-12-30
US11491163B2 (en) 2022-11-08
JP2018199740A (ja) 2018-12-20
PL3628670T3 (pl) 2023-02-20
IL235045B (en) 2019-05-30
KR20220123339A (ko) 2022-09-06
CA2870005C (en) 2021-06-22
HRP20191653T1 (hr) 2020-02-21
US12251386B2 (en) 2025-03-18
EP2836491A1 (en) 2015-02-18
IL266165A (en) 2019-06-30
KR102120883B1 (ko) 2020-06-09
SG11201406468YA (en) 2015-01-29
EP3184523A1 (en) 2017-06-28
DK3628670T3 (da) 2022-12-05
ES2745016T3 (es) 2020-02-27
IL296199B2 (en) 2024-12-01
PL3184523T3 (pl) 2019-12-31
SI3184523T1 (sl) 2020-04-30
SMT201900501T1 (it) 2019-11-13
US10245269B2 (en) 2019-04-02

Similar Documents

Publication Publication Date Title
US12251386B2 (en) Salt form of a human histone methyltransferase EZH2 inhibitor
HK40087682A (en) Hbr salt form for ezh2 inhibition
HK40026825A (en) Salt form for ezh2 inhibition
HK40026825B (en) Salt form for ezh2 inhibition

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200601

Application number text: 1020147030684

Filing date: 20141031

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200630

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200901

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20210715

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220125

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210715

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20200901

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220125

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210225

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20220525

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220422

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220125

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210225

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220825

Application number text: 1020147030684

Filing date: 20141031

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220826

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220826

End annual number: 3

Start annual number: 1

PG1601 Publication of registration